立体定向消融放疗治疗异时性肺癌与原发性肺癌的结局比较
该回顾性研究分析了137例接受立体定向消融放疗(SABR)的I期非小细胞肺癌患者,其中异时性肺癌(MLC)28例(20.4%),原发性肺癌(PLC)109例(79.6%)。结果显示两组在3年局部控制率、无进展生存率、总生存率及毒性发生率方面均无显著差异。作者结论认为SABR是治疗局限性异时性肺癌安全有效的方法。
要点
- 137例I期非小细胞肺癌患者接受SABR,其中MLC 28例(20.4%),PLC 109例(79.6%)。
- MLC组与PLC组3年局部控制率分别为83.6%与72.6%(p=0.2),无显著差异。
- MLC组与PLC组3年总生存率分别为78.6%与52.1%(p=0.9),无显著差异。
核心结论
- 作者结论认为SABR是治疗局限性异时性肺癌安全有效的方法。
研究设计与样本
- 回顾性分析137例接受SABR治疗的I期非小细胞肺癌患者,其中MLC 28例(20.4%),PLC 109例(79.6%)。
主要发现
- MLC组与PLC组中位年龄分别为76.6岁与78.6岁(p=0.2)。
- MLC组与PLC组3年局部控制率分别为83.6%与72.6%(p=0.2)。
- MLC组与PLC组3年无进展生存率分别为68.7%与50.9%(p=0.9)。
- MLC组与PLC组3年总生存率分别为78.6%与52.1%(p=0.9)。
- MLC组与PLC组总毒性发生率分别为54.1%与42.9%(p=0.6),3级及以上毒性发生率分别为3.7%与3.6%(p=0.9)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early-stage lung cancer, primarily treated with surgery, often occur in poor surgical candidates (impaired respiratory function, prior thoracic surgery, severe comorbidities). Stereotactic ablative radiotherapy (SABR) is a non-invasive alternative that provides comparable local control. This technique is particularly relevant for surgically resectable metachronous lung cancer, in patients unable to undergo surgery.. The objective of this study is to evaluate the clinical outcome of patients treated with SABR for stage I metachronous lung cancer (MLC) versus stage I primary lung cancer (PLC). PATIENTS AND METHODS: 137 patients treated with SABR for stage I non-small cell lung cancer were retrospectively reviewed, of which 28 (20.4%) were MLC and 109 (79.6%) were PLC. Cohorts were evaluated for differences in overall survival (OS), progression-free survival (PFS), metastasis-free survival, local control (LC), and toxicity. RESULTS: After SABR, patients treated for MLC have comparable median age (76.6 vs 78.6, p = 0.2), 3-year LC (83.6% vs. 72.6%, p = 0.2), PFS (68.7% vs. 50.9%, p = 0.9), and OS (78.6% vs. 52.1%, p = 0.9) as PLC, along with similar rates of total (54.1% vs. 42.9%, p = 0.6) and grade 3 + toxicity (3.7% vs. 3.6%, p = 0.9). Previous treatment of MLC patients was either surgery (21/28, 75%) or SABR (7/28, 25%). The median follow-up was 53 months. CONCLUSION: SABR is a safe and effective approach for localized metachronous lung cancer.
引用
- Benzaquen J, Bondiau PY, Otto J, et al. Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer. Radiat Oncol. 2023. PMID: 37287020. doi:10.1186/s13014-023-02286-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。